Analysts Anticipate Masimo (MASI) Will Announce Quarterly Sales of $206.24 Million

Analysts forecast that Masimo (NASDAQ:MASI) will announce sales of $206.24 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Masimo’s earnings, with the highest sales estimate coming in at $208.00 million and the lowest estimate coming in at $204.10 million. Masimo posted sales of $186.30 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.7%. The firm is expected to issue its next earnings report after the market closes on Wednesday, May 2nd.

On average, analysts expect that Masimo will report full year sales of $206.24 million for the current financial year, with estimates ranging from $836.06 million to $837.00 million. For the next financial year, analysts expect that the firm will report sales of $884.84 million per share, with estimates ranging from $881.43 million to $888.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Masimo.

How to Become a New Pot Stock Millionaire

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.11. Masimo had a return on equity of 22.75% and a net margin of 16.49%. The business had revenue of $225.20 million for the quarter, compared to the consensus estimate of $201.54 million. During the same quarter in the prior year, the business posted $0.46 EPS. The business’s revenue for the quarter was up 22.9% on a year-over-year basis.

A number of research analysts recently issued reports on the company. BidaskClub upgraded Masimo from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research note on Tuesday, March 6th. Barclays assumed coverage on Masimo in a research note on Friday, March 9th. They set an “overweight” rating and a $97.00 price target on the stock. Finally, Piper Jaffray restated a “hold” rating and set a $91.00 price target on shares of Masimo in a research note on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $101.00.

In related news, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $86.02, for a total transaction of $172,040.00. Following the transaction, the director now owns 66,249 shares in the company, valued at approximately $5,698,738.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jon Coleman sold 29,303 shares of the firm’s stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $87.50, for a total value of $2,564,012.50. Following the transaction, the insider now owns 20,504 shares in the company, valued at approximately $1,794,100. The disclosure for this sale can be found here. Insiders have sold a total of 45,403 shares of company stock worth $4,040,693 in the last 90 days. 16.60% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in MASI. New York State Common Retirement Fund grew its stake in shares of Masimo by 7.8% in the 3rd quarter. New York State Common Retirement Fund now owns 63,410 shares of the medical equipment provider’s stock valued at $5,489,000 after purchasing an additional 4,594 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of Masimo by 0.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 268,353 shares of the medical equipment provider’s stock valued at $23,228,000 after purchasing an additional 1,930 shares during the last quarter. Macquarie Group Ltd. purchased a new position in shares of Masimo in the 3rd quarter valued at approximately $493,000. Nordea Investment Management AB grew its stake in shares of Masimo by 25.3% in the 3rd quarter. Nordea Investment Management AB now owns 24,816 shares of the medical equipment provider’s stock valued at $2,148,000 after purchasing an additional 5,012 shares during the last quarter. Finally, Great West Life Assurance Co. Can grew its stake in shares of Masimo by 4.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 28,031 shares of the medical equipment provider’s stock valued at $2,379,000 after purchasing an additional 1,118 shares during the last quarter. Institutional investors own 82.79% of the company’s stock.

NASDAQ:MASI traded down $2.80 during mid-day trading on Tuesday, reaching $83.88. 282,616 shares of the stock were exchanged, compared to its average volume of 503,907. The company has a market capitalization of $4,331.23, a PE ratio of 34.24, a P/E/G ratio of 2.20 and a beta of 0.94. Masimo has a 1 year low of $80.69 and a 1 year high of $104.71.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Masimo (MASI) Will Announce Quarterly Sales of $206.24 Million” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3341717/analysts-anticipate-masimo-masi-will-announce-quarterly-sales-of-206-24-million.html.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RHFCoin Trading 3% Higher  Over Last Week
RHFCoin Trading 3% Higher Over Last Week
HomeBlockCoin Achieves Market Capitalization of $80,948.00
HomeBlockCoin Achieves Market Capitalization of $80,948.00
Comparing Ensign Group  & Genesis HealthCare
Comparing Ensign Group & Genesis HealthCare
Contrasting Moelis & Company  & The Competition
Contrasting Moelis & Company & The Competition
Financial Comparison: Intrexon  versus Sorrento Therapeutics
Financial Comparison: Intrexon versus Sorrento Therapeutics
$713.23 Million in Sales Expected for Genesis Energy, L.P.  This Quarter
$713.23 Million in Sales Expected for Genesis Energy, L.P. This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.